Despite mutations in isocitrate dehydrogenase (IDH) and co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p/19q) have been identified as critical indicators for disease diagnosis, treatment option and prognostic evaluation (Wick et al., 2014; Lee et al., 2018), targeting these molecular markers still has minimal effects on glioma patients. Here, IDH1 is linked to central nervous system cancer.